Genmab

Genmab is a public international biotechnology company specializing in creating and developing differentiated therapeutic agents for cancer treatment. It was founded in 1999. It has a wide clinical and preclinical range of products and four patented new generation antibody technologies.
Genmab stock price chart
vol.
change
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Genmab balance sheet

Report period2019 2020 2021 2022 2023 Q1 24
End date of the reporting period
Capitalization, kr.
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Genmab cash flows

Report period2019 2020 2021 2022 2023 Q1 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Genmab multipliers

Report period2019 2020 2021 2022 2023 Q1 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Genmab profitability

Report period2019 2020 2021 2022 2023 Q1 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Genmab assets
Genmab cash flows

Genmab shares

TickerNameTypeNominal valueISINPrice
GMAB:USGenmab A/SDepositary receipt-DK0010272202$22.9
Genmab news
21.09.2021
Genmab has received accelerated FDA approval for TIVDAK, developed in collaboration with Seagen. The drug is intended to treat adults with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy.
Source: {source} pictogram ir.genmab.com
Pictogram next
05.11.2020
Genmab's net profit under IFRS for 9 months of 2020 was kr.4.177 billion, up 6 times from kr.0.694 billion in the previous year. Revenue increased 3.4 times to kr.8.067 billion compared to kr.2.405 billion a year earlier.
Source: {source} pictogram ir.genmab.com
Pictogram next
All Genmab news
General information
Company nameGenmab
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressTOLDBODGADE 33 1253 COPENHAGEN K G7 00000
Mailing addressTOLDBODGADE 33 1253 COPENHAGEN K G7 00000
Websitewww.genmab.com